Local Delivery of Paclitaxel Via the TAPAS Catheter to Prevent Restenosis From Percutaneous Femoropopliteal Intervention

Inclusion Criteria: * Age ≥ 18 years old. * Subject able to provide informed consent and agree to all follow up requirements. * Peripheral arterial disease with Rutherford Class 2-5. * Successful percutaneous revascularization of the femoropopliteal artery (\< 20% residual stenosis by visual estimate) using standard techniques per discretion of the local operator. * The femoropopliteal Reference Vessel Diameter (RVD) must be ≥4.0 mm and ≤7.0 mm Exclusion Criteria: * Patient is pregnant or breast feeding. (Female subjects of childbearing potential must have negative serum pregnancy test the day of the procedure.) * Life expectancy \< 12 months. * Contraindication to aspirin, anti-platelet/anti-coagulant therapies required for procedure/follow up. * Known allergy to contrast media that cannot adequately be pre-medicated prior to study procedure. * Known allergy to paclitaxel. * Uncontrolled hypercoagulability or history of HIT or HITTS syndrome. * Simultaneous enrollment in another investigational device or drug study. * Previous intervention of the target limb with a drug eluting stent or drug eluting balloon. * Absence of at least 1 TIMI-3 vessel run off into the foot. * Total bilirubin \> 2x upper limit of normal (ULN). * ALT or AST \> 3x ULN. * Platelet count \< 100,000/mm3. * White blood cell count \< 1.5/mm3. * Any evidence of perforation or dye extravasation during the index procedure, even if successfully treated with a covered stent.